Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
Rohit K Jain, Hongbin Chen Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Crizotinib was...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-10-01
|
| Series: | Lung Cancer : Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/spotlight-on-brigatinib-and-its-potential-in-the-treatment-of-patients-peer-reviewed-article-LCTT |